CytomX Therapeutics, Inc. (CTMX) PT Raised to $44.00
CytomX Therapeutics, Inc. (NASDAQ:CTMX) had its price objective boosted by analysts at Nomura to $44.00 in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Nomura’s price objective would indicate a potential upside of 99.46% from the company’s current price.
A number of other equities analysts have also recently commented on the company. Cowen and Company reiterated a “buy” rating on shares of CytomX Therapeutics in a report on Wednesday, June 28th. Jefferies Group LLC restated a “buy” rating and set a $25.00 price objective on shares of CytomX Therapeutics in a report on Tuesday, June 6th. BidaskClub upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 8th. ValuEngine cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Finally, Wedbush began coverage on CytomX Therapeutics in a report on Thursday, September 7th. They set an “outperform” rating and a $26.00 price objective for the company. Two analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $32.67.
CytomX Therapeutics (NASDAQ:CTMX) traded down 2.7647% during mid-day trading on Wednesday, hitting $21.4501. The stock had a trading volume of 174,968 shares. CytomX Therapeutics has a 12 month low of $9.85 and a 12 month high of $24.67. The stock’s 50-day moving average price is $17.15 and its 200-day moving average price is $15.67. The stock’s market cap is $790.80 million.
CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). The company had revenue of $8.75 million during the quarter, compared to analysts’ expectations of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. On average, analysts predict that CytomX Therapeutics will post ($1.47) earnings per share for the current year.
WARNING: “CytomX Therapeutics, Inc. (CTMX) PT Raised to $44.00” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/06/cytomx-therapeutics-inc-ctmx-pt-raised-to-44-00.html.
In related news, major shareholder Robert I. Tepper sold 24,777 shares of the business’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $24.34, for a total transaction of $603,072.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Robert I. Tepper sold 20,000 shares of the business’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $18.00, for a total value of $360,000.00. Following the transaction, the insider now owns 54,293 shares of the company’s stock, valued at approximately $977,274. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 100,306 shares of company stock valued at $1,924,746. 4.70% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of CTMX. Teachers Advisors LLC boosted its holdings in CytomX Therapeutics by 6.7% during the 4th quarter. Teachers Advisors LLC now owns 34,961 shares of the biotechnology company’s stock valued at $384,000 after acquiring an additional 2,209 shares during the period. Strs Ohio purchased a new stake in shares of CytomX Therapeutics in the 1st quarter worth $207,000. Wells Fargo & Company MN lifted its holdings in shares of CytomX Therapeutics by 52.8% in the 1st quarter. Wells Fargo & Company MN now owns 22,424 shares of the biotechnology company’s stock worth $387,000 after buying an additional 7,747 shares during the period. Swiss National Bank lifted its holdings in shares of CytomX Therapeutics by 19.1% in the 1st quarter. Swiss National Bank now owns 26,800 shares of the biotechnology company’s stock worth $463,000 after buying an additional 4,300 shares during the period. Finally, Oxford Asset Management lifted its holdings in shares of CytomX Therapeutics by 28.4% in the 1st quarter. Oxford Asset Management now owns 31,665 shares of the biotechnology company’s stock worth $547,000 after buying an additional 6,995 shares during the period. Institutional investors own 59.97% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.